Nature metabolism

Rare GLP1R gene changes reduce weight loss with semaglutide but not tirzepatide

Updated

Abstract

Among 13,725 GLP-1RA-treated adults, carriers of rare damaging GLP1R variants lose less weight with semaglutide but achieve a near-normal response with tirzepatide.

  • Carriers of rare GLP1R variants exhibit reduced weight loss when treated with semaglutide compared to matched non-carriers.
  • Tirzepatide treatment results in near-normal weight loss responses for individuals with rare GLP1R variants.
  • Normal weight loss responses are observed in carriers of rare GIPR variants, which target the glucose-dependent insulinotropic polypeptide receptor.
  • The findings indicate that rare genetic variants may influence the efficacy of specific GLP-1 receptor agonists.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free